Teva Pharmaceutical

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell TEVA and other ETFs, options, and stocks.

About TEVA

Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: United States, Europe, and International Markets. 

CEO
Richard Francis
CEORichard Francis
Employees
36,167
Employees36,167
Headquarters
Tel Aviv, Tel Aviv
HeadquartersTel Aviv, Tel Aviv
Founded
1901
Founded1901
Employees
36,167
Employees36,167

TEVA Key Statistics

Market cap
35.59B
Market cap35.59B
Price-Earnings ratio
49.57
Price-Earnings ratio49.57
Dividend yield
Dividend yield
Average volume
10.16M
Average volume10.16M
High today
$31.10
High today$31.10
Low today
$30.45
Low today$30.45
Open price
$30.72
Open price$30.72
Volume
3.61M
Volume3.61M
52 Week high
$31.10
52 Week high$31.10
52 Week low
$12.47
52 Week low$12.47

Stock Snapshot

As of today, Teva Pharmaceutical(TEVA) shares are valued at $31.04. The company's market cap stands at 35.59B, with a P/E ratio of 49.57.

On 2025-12-22, Teva Pharmaceutical(TEVA) stock traded between a low of $30.45 and a high of $31.10. Shares are currently priced at $31.04, which is +1.9% above the low and -0.2% below the high.

The Teva Pharmaceutical(TEVA)'s current trading volume is 3.61M, compared to an average daily volume of 10.16M.

During the past year, Teva Pharmaceutical(TEVA) stock moved between $12.47 at its lowest and $31.10 at its peak.

During the past year, Teva Pharmaceutical(TEVA) stock moved between $12.47 at its lowest and $31.10 at its peak.

TEVA News

TipRanks 4d
Top Teva Executives Quietly Cash Out in Major Stock Sell-Off

New insider activity at Teva Pharmaceutical ( (TEVA) ) has taken place on December 18, 2025. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock he...

Simply Wall St 5d
Teva Secures Revolver Extension: A Subtle Shift In Balance Sheet Risk Or Strategy?

In December 2025, Teva Pharmaceutical Industries obtained lender consent to extend the maturity of its senior unsecured sustainability-linked revolving credit f...

Teva Secures Revolver Extension: A Subtle Shift In Balance Sheet Risk Or Strategy?

Analyst ratings

83%

of 12 ratings
Buy
83.3%
Hold
8.3%
Sell
8.3%
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.